- Vaxil Bio Ltd. (VXL) is pleased to announce that Dr. Michael Berelowitz has been appointed as a special advisor to its board
- Berelowitz, formerly Pfizer’s Head of Clinical Development and Medical Affairs (Specialty Care), has over 50 years of experience in the biomedical sciences
- Berelowitz has served on numerous company boards, including several public companies
- Vaxil Bio’s Chairman and CEO David Goren said the biotech company is pleased to welcome Berelowitz as a special advisor to its board
- Vaxil Bio Ltd. is up 14.29 per cent to C$0.48 per share
Vaxil Bio Ltd. (VXL) is pleased to announce that Dr. Michael Berelowitz has been appointed as a special advisor to its board.
Berelowitz, formerly Pfizer’s Head of Clinical Development and Medical Affairs (Specialty Care), has over 50 years of experience in the biomedical sciences.
Berelowitz has served on numerous company boards, including several public companies. The company said Berelowitz’s diverse experience provides him with a unique and valuable understanding of the world’s biopharmaceuticals.
Vaxil Bio’s Chairman and CEO David Goren said the biotech company is pleased to welcome Berelowitz as a special advisor to its board.
“His extensive and relevant experience will significantly add to our talented team of executives and scientists. I am excited to be able to bring his medical background together with business acumen to support our portfolio and future growth as we progress through preclinical and future clinical phases.”
Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes, and metabolic disorders.
Berelowitz has been granted 125,000 stock options pursuant to the company’s stock option plan, exercisable into an equal amount of common shares in the capital of the Company at an exercise price of CAD $0.42 per common share.
The options vest in four equal installments, with the first installment on March 31, 2021, and the subsequent installments on June 30, 2021, September 30, 2021 and December 31, 2021 respectively. All the options expire on February 1, 2026.
Vaxil Bio Ltd. is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases.
Vaxil Bio Ltd. is up 14.29 per cent to C$0.48 per share.
